Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells

Journal of Nutritional Biochemistry

Volumn 24, Issue 9, 2013, Pages 1596-1603

  Huang, Chun Yin ^a   Chan, Chien Yi ^a   Chou, I Tai ^a   Lien, Chia Hsien ^a   Hung, Hsiao Chi ^a   Lee, Ming Fen ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

EGFR; FOXO1; Oral cancer; Quercetin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; QUERCETIN; TRANSCRIPTION FACTOR FKHR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUTH CANCER; REGULATORY MECHANISM;

MUS;

EID: 84881541389     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.01.010     Document Type: Article

References (55)

1. Sheu J.J., Hua C.H., Wan L., Lin Y.J., Lai M.T., Tseng H.C., et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009, 69:2568-2576.
2. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-4176.
3. Temam S., Kawaguchi H., El-Naggar A.K., Jelinek J., Tang H., Liu D.D., et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007, 25:2164-2170.
4. Modjtahedi H., Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009, 20:851-855.
5. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005, 5:1085-1093.
6. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
7. Dobelbower M.C., Russo S.M., Raisch K.P., Seay L.L., Clemons L.K., Suter S., et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006, 17:95-102.
8. Ratushny V., Astsaturov I., Burtness B.A., Golemis E.A., Silverman J.S. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009, 21:1255-1268.
9. Lamson D.W., Brignall M.S. Antioxidants and cancer, part 3: quercetin. Altern Med Rev 2000, 5:196-208.
10. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996, 2:659-668.
11. Le Marchand L., Murphy S.P., Hankin J.H., Wilkens L.R., Kolonel L.N. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000, 92:154-160.
12. Vargas A.J., Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev 2010, 68:418-428.
13. Xiao X., Shi D., Liu L., Wang J., Xie X., Kang T., et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One 2011, 6:e22934.
14. Vidya Priyadarsini R., Senthil Murugan R., Maitreyi S., Ramalingam K., Karunagaran D., Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappaB inhibition. Eur J Pharmacol 2010, 649:84-91.
15. Zhang Q., Zhao X.H., Wang Z.J. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro 2009, 23:797-807.
16. Rubio S., Quintana J., Eiroa J.L., Triana J., Estevez F. Acetyl derivative of quercetin 3-methyl ether-induced cell death in human leukemia cells is amplified by the inhibition of ERK. Carcinogenesis 2007, 28:2105-2113.
17. Vijayababu M.R., Kanagaraj P., Arunkumar A., Ilangovan R., Aruldhas M.M., Arunakaran J. Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol 2005, 131:765-771.
18. Choi J.A., Kim J.Y., Lee J.Y., Kang C.M., Kwon H.J., Yoo Y.D., et al. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol 2001, 19:837-844.
19. Beniston R.G., Campo M.S. Quercetin elevates p27(Kip1) and arrests both primary and HPV16 E6/E7 transformed human keratinocytes in G1. Oncogene 2003, 22:5504-5514.
20. Wang P., Zhang K., Zhang Q., Mei J., Chen C.J., Feng Z.Z., et al. Effects of quercetin on the apoptosis of the human gastric carcinoma cells. Toxicol In Vitro 2012, 26:221-228.
21. Jeong J.H., An J.Y., Kwon Y.T., Li L.Y., Lee Y.J. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem 2008, 105:585-595.
22. Ranelletti F.O., Maggiano N., Serra F.G., Ricci R., Larocca L.M., Lanza P., et al. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer 2000, 85:438-445.
23. Avila M.A., Velasco J.A., Cansado J., Notario V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 1994, 54:2424-2428.
24. Casagrande F., Darbon J.M. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 2001, 61:1205-1215.
25. Matter W.F., Brown R.F., Vlahos C.J. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun 1992, 186:624-631.
26. Gulati N., Laudet B., Zohrabian V.M., Murali R., Jhanwar-Uniyal M. The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res 2006, 26:1177-1181.
27. Sun Z.J., Chen G., Hu X., Zhang W., Liu Y., Zhu L.X., et al. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 2010, 15:850-863.
28. Chowdhury S.A., Kishino K., Satoh R., Hashimoto K., Kikuchi H., Nishikawa H., et al. Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res 2005, 25:2055-2063.
29. Kang J.W., Kim J.H., Song K., Kim S.H., Yoon J.H., Kim K.S. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells. Phytother Res 2010, 24(Suppl 1):S77-S82.
30. Haghiac M., Walle T. Quercetin induces necrosis and apoptosis in SCC-9 oral cancer cells. Nutr Cancer 2005, 53:220-231.
31. Kaestner K.H., Knochel W., Martinez D.E. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000, 14:142-146.
32. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
33. Zhao Y., Wang Y., Zhu W.G. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol 2011, 3:276-282.
34. Essaghir A., Dif N., Marbehant C.Y., Coffer P.J., Demoulin J.B. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009, 284:10334-10342.
35. Maiese K., Chong Z.Z., Shang Y.C. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008, 14:219-227.
36. Kim S.Y., Yoon J., Ko Y.S., Chang M.S., Park J.W., Lee H.E., et al. Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules. BMC Cancer 2011, 11:264.
37. Katayama K., Nakamura A., Sugimoto Y., Tsuruo T., Fujita N. FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression. Oncogene 2008, 27:1677-1686.
38. Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J., et al. Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner. Cancer Res 2011, 71:946-954.
39. Suhara T., Kim H.S., Kirshenbaum L.A., Walsh K. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 2002, 22:680-691.
40. Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010, 12:665-675.
41. Zhang H., Pan Y., Zheng L., Choe C., Lindgren B., Jensen E.D., et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011, 71:3257-3267.
42. Boreddy S.R., Pramanik K.C., Srivastava S.K. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res 2011, 17:1784-1795.
43. Chakrabarty A., Sanchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 2011.
44. Chen Q., Ganapathy S., Singh K.P., Shankar S., Srivastava R.K. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010, 5:e15288.
45. Roy S.K., Chen Q., Fu J., Shankar S., Srivastava R.K. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 2011, 6:e25166.
46. Wu Y., Shang X., Sarkissyan M., Slamon D., Vadgama J.V. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 2010, 70:5475-5485.
47. Hseu Y.C., Lee M.S., Wu C.R., Cho H.J., Lin K.Y., Lai G.H., et al. The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway. J Agric Food Chem 2012, 60:2385-2397.
48. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992, 11:961-971.
49. Foijer F., te Riele H. Check, double check: the G2 barrier to cancer. Cell Cycle 2006, 5:831-836.
50. Ravid T., Sweeney C., Gee P., Carraway K.L., Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. J Biol Chem 2002, 277:31214-31219.
51. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
52. Kozaki K., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H., Omura K., et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006, 97:1351-1358.
53. Seoane J., Le H.V., Shen L., Anderson S.A., Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
54. Yamaza H., Komatsu T., Wakita S., Kijogi C., Park S., Hayashi H., et al. FoxO1 is involved in the antineoplastic effect of calorie restriction. Aging Cell 2010, 9:372-382.
55. Sakai E., Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992, 7:927-933.